Mild cognitive impairment, early Alzheimer’s patients needed for local study

Individuals living with Mild Cognitive Impairment and/or early Alzheimer’s disease are invited to participate in an ongoing medication research study.

Okanagan Clinical Trials, a medical research company in Kelowna, is currently conducting a study to determine the effectiveness of an investigational medication for Mild Cognitive Impairment and/or early Alzheimer’s Disease.

“Alzheimer’s disease is a devastating condition with very few viable treatment options,” said Dr. Paul Latimer, psychiatrist and principal investigator for Okanagan Clinical Trials. “With an aging population and numbers on the rise, it is very important to continue searching for safe and effective treatments.”

Alzheimer’s disease is the most common form of dementia and affects almost 30 million people worldwide. It is a progressive condition with no cure. Typically, it begins by affecting an individual’s short-term memory. It worsens over time and eventually leads to death. Most often, Alzheimer’s affects people over the age of 65, but some develop early onset Alzheimer’s much earlier in life.

Eligible volunteers for this study will be men and women between the ages of 55-79 with complaints of memory impairment. More than 600 patients will participate in this Phase 3 clinical study. Okanagan Clinical Trials was selected to participate because of its proven track record in conducting clinical trials since 1992.

Effects of the study medication will be measured initially over one year. Treatment will not affect provincial medical coverage and all study-related costs will be paid for by the sponsor. Participants may be reimbursed for travel and are free to leave the study at any time.

Contact Okanagan Clinical Trials at 250-862-8141.